2019
DOI: 10.1007/s00417-019-04471-3
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
13
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 10 publications
(14 citation statements)
references
References 27 publications
1
13
0
Order By: Relevance
“…Serous RD (SRD) is a subgroup of RD commonly seen in central serous chorioretinopathy (CSC) and diabetic macular edema (DME) [10,11]. DME with coexisting SRD (SRD-DME) can be observed in the OCT images of DME patients [10].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Serous RD (SRD) is a subgroup of RD commonly seen in central serous chorioretinopathy (CSC) and diabetic macular edema (DME) [10,11]. DME with coexisting SRD (SRD-DME) can be observed in the OCT images of DME patients [10].…”
Section: Introductionmentioning
confidence: 99%
“…Serous RD (SRD) is a subgroup of RD commonly seen in central serous chorioretinopathy (CSC) and diabetic macular edema (DME) [10,11]. DME with coexisting SRD (SRD-DME) can be observed in the OCT images of DME patients [10]. Photoreceptor damage can also be seen in eyes with SRD-DME and the photoreceptors can be restored after resolution of the DME [12][13][14].…”
Section: Introductionmentioning
confidence: 99%
“…We included eyes that were untreated or received previous anti-vascular endothelial growth factor (VEGF) or pan-retinal photocoagulation (PRP) at least 6 months ago and eyes with the central foveal thickness (CFT) over 275 µm and BCVA between 0.3 and 1.0 logarithm of the minimal angle of resolution (LogMAR) (20/200-20/40) at baseline (12,19). Eyes with macular edema secondary to other causes, such as retinal artery/vein occlusion, age-related macular degeneration, and polypoidal choroidal vasculopathy, eyes with macular ischemia, glaucoma or IOP > 21 mmHg, a history of macular grid photocoagulation or vitrectomy, refractive error over 6 diopters (D), severe cataracts, or previously treated with PRP or intravitreal or periocular injection <6 months were excluded (12,17). We also excluded eyes with unsatisfactory SD-OCT images resulting from poor patient cooperation or media opacity.…”
Section: Subjectsmentioning
confidence: 99%
“…All included eyes received a loading dose of 3 monthly consecutive 0.5-mg intravitreal injections of ranibizumab (IVR) treatment. After the loading treatment, patients were followed on monthly basis and received 1 IVR injection if they met any of the following criteria: (A) CFT increases by ≥ 100 µm; (B) BCVA decreases by ≥ 0.1 LogMAR; or (C) the decrease of BCVA attributed to newly formed SRD or intraretinal cyst, based on the surgeons; or (D) the decrease of BCVA due to enlargement of previous SRD or intraretinal cyst, based on the surgeons (9,12,17). IVR injection was suspended if either of the following criteria was met: (A) BCVA ≤ 0.0 LogMAR (20/20) observed at the two last consecutive follow-ups; or (B) stable BCVA over three consecutive follow-ups that include the current follow-up evaluation, specifically no improvement of BCVA due to IVR injections at the two last consecutive follow-ups (9,12,17).…”
Section: Treatmentmentioning
confidence: 99%
See 1 more Smart Citation